John A. O's most recent trade in B&G Foods, Inc was a trade of 37,571 Common Stock done . Disclosure was reported to the exchange on March 25, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| B&G Foods Inc | John A. Ozgopoyan | EVP of Sales | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2026 | 37,571 | 37,571 (0%) | 0% | 0 | Common Stock | |
| Cactus Inc (Class A) | John A. O'Donnell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2026 | 2,559 | 5,083 | - | - | Restricted Stock Units | |
| Cactus Inc (Class A) | John A. O'Donnell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 2,524 | 2,559 | - | - | Restricted Stock Units | |
| Cactus Inc (Class A) | John A. O'Donnell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 2,524 | 27,990 (0%) | 0% | - | Class A Common Stock | |
| Westinghouse Air Brake Tech | John A. Olin | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2026 | 5,917 | 61,893 (0%) | 0% | 0 | Common Stock - Direct | |
| Ensign Grp Inc | John O. Agwunobi | Director | Sale of securities on an exchange or to another person at price $ 179.82 per share. | 20 Jan 2026 | 246 | 9,233 (0%) | 0% | 179.8 | 44,236 | Common Stock |
| Ensign Grp Inc | John O. Agwunobi | Director | Sale of securities on an exchange or to another person at price $ 178.31 per share. | 20 Jan 2026 | 146 | 9,087 (0%) | 0% | 178.3 | 26,033 | Common Stock |
| Ensign Grp Inc | John O. Agwunobi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2026 | 600 | 9,479 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 8,250 | 8,250 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 6,000 | 6,000 | - | - | Restricted Stock Unit | |
| Herc Holdings Inc | John A. Olin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2026 | 320 | 320 (0%) | 0% | 0 | Common Stock | |
| Bruker Corp | John A. Ornell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.00 per share. | 06 Nov 2025 | 10,000 | 41,445 (0%) | 0% | 24 | 240,000 | Common Stock |
| Bruker Corp | John A. Ornell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2025 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Bruker Corp | John A. Ornell | Director | Sale of securities on an exchange or to another person at price $ 39.00 per share. | 06 Nov 2025 | 6,233 | 35,212 (0%) | 0% | 39 | 243,087 | Common Stock |
| Ensign Grp Inc | John O. Agwunobi | Director | Sale of securities on an exchange or to another person at price $ 188.87 per share. | 06 Nov 2025 | 246 | 8,879 (0%) | 0% | 188.9 | 46,462 | Common Stock |
| Ensign Grp Inc | John O. Agwunobi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2025 | 600 | 9,125 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2025 | 1,300 | 10,665 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2025 | 1,300 | 1,300 | - | - | Restricted Stock Unit | |
| CARGO Therapeutics Inc | John A. Orwin | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Aug 2025 | 25,000 | 0 | - | - | Stock Option (Right to Buy) | |
| CARGO Therapeutics Inc | John A. Orwin | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 19 Aug 2025 | 15,865 | 0 | - | - | Stock Option (Right to Buy) | |
| Ensign Grp Inc | John O. Agwunobi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2025 | 600 | 8,525 (0%) | 0% | 0 | Common Stock | |
| CARGO Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| AnaptysBio Inc | John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2025 | 6,030 | 9,365 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2025 | 6,030 | 0 | - | - | Restricted Stock Unit | |
| Travere Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 19,500 | 19,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 6,500 | 35,375 (0%) | 0% | 0 | Common Stock | |
| Bruker Corp | John A. Ornell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 5,000 | 0 | - | - | Stock Option (right to buy) | |
| Bruker Corp | John A. Ornell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.15 per share. | 13 May 2025 | 5,000 | 31,445 (0%) | 0% | 18.2 | 90,750 | Common Stock |
| Ensign Grp Inc | John O. Agwunobi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2025 | 600 | 7,925 (0%) | 0% | 0 | Common Stock | |
| Westinghouse Air Brake Tech | John A. Olin | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 7,906 | 57,405 (0%) | 0% | 0 | Common Stock - Direct | |
| Cactus Inc (Class A) | John A. O'Donnell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 3,116 | 2,524 | - | - | Restricted Stock Units | |
| Cactus Inc (Class A) | John A. O'Donnell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 3,116 | 25,466 (0%) | 0% | - | Class A Common Stock | |
| Cactus Inc (Class A) | John A. O'Donnell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 2,524 | 5,640 | - | - | Restricted Stock Units | |
| Westinghouse Air Brake Tech | John A. Olin | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 183.87 per share. | 03 Mar 2025 | 4,254 | 49,499 (0%) | 0% | 183.9 | 782,183 | Common Stock - Direct |
| Bruker Corp | John A. Ornell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 3,298 | 26,445 (0%) | 0% | 0 | Common Stock | |
| Westinghouse Air Brake Tech | John A. Olin | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 194.11 per share. | 13 Feb 2025 | 23,766 | 64,587 (0%) | 0% | 194.1 | 4,613,128 | Common Stock - Direct |
| Westinghouse Air Brake Tech | John A. Olin | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 194.11 per share. | 13 Feb 2025 | 10,834 | 53,753 (0%) | 0% | 194.1 | 2,102,947 | Common Stock - Direct |
| Ensign Grp Inc | John O. Agwunobi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2025 | 600 | 7,325 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| Bluebird bio Inc | John O. Agwunobi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2024 | 49,850 | 49,850 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | John O. Agwunobi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Nov 2024 | 24,900 | 51,364 (0%) | 0% | 0 | Common Stock | |
| Ensign Grp Inc | John O. Agwunobi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2024 | 600 | 6,725 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2024 | 1,300 | 2,600 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2024 | 1,300 | 3,335 (0%) | 0% | 0 | Common Stock | |
| Westinghouse Air Brake Tech | John A. Olin | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 168.04 per share. | 30 Aug 2024 | 5,165 | 40,821 (0%) | 0% | 168.0 | 867,901 | Common Stock - Direct |
| Ensign Grp Inc | John O. Agwunobi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 875 | 6,125 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 2,035 | 0 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | John A. Orwin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 2,035 | 2,035 (0%) | 0% | 0 | Common Stock | |
| CARGO Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2024 | 23,742 | 23,742 | - | - | Stock Option (Right to Buy) | |
| Travere Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 19,500 | 19,500 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 6,500 | 28,875 (0%) | 0% | 0 | Common Stock | |
| Ensign Grp Inc | John O. Agwunobi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 875 | 5,250 (0%) | 0% | 0 | Common Stock | |
| Atreca Inc Ordinary Shares | John A. Orwin | Director, PRESIDENT & CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 11 Apr 2024 | 1 | 1 | - | 0 | Series A Junior Preferred Stock | |
| Cactus Inc (Class A) | John A. O'Donnell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2024 | 3,116 | 3,116 | - | - | Restricted Stock Units | |
| Cactus Inc (Class A) | John A. O'Donnell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 2,037 | 22,350 (0%) | 0% | - | Class A Common Stock | |
| Cactus Inc (Class A) | John A. O'Donnell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 2,037 | 0 | - | - | Restricted Stock Units | |
| Westinghouse Air Brake Tech | John A. Olin | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 9,815 | 45,986 (0%) | 0% | 0 | Common Stock - Direct | |
| Westinghouse Air Brake Tech | John A. Olin | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 141.62 per share. | 01 Mar 2024 | 2,843 | 36,171 (0%) | 0% | 141.6 | 402,619 | Common Stock - Direct |
| Ensign Grp Inc | John Agwunobi O. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 875 | 4,375 (0%) | 0% | 0 | Common Stock | |
| Bruker Corp | Ornell John A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 2,377 | 23,147 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | A. John Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2024 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| Atreca Inc Ordinary Shares | John A. Orwin | Director, PRESIDENT & CEO | Sale of securities on an exchange or to another person at price $ 0.37 per share. | 01 Sep 2023 | 22,951 | 77,541 (0%) | 0% | 0.4 | 8,597 | Class A Common Stock |
| Cactus Inc (Class A) | John A. O'Donnell | Director | Sale of securities on an exchange or to another person at price $ 50.95 per share. | 18 Aug 2023 | 27,508 | 20,313 (0%) | 0% | 50.9 | 1,401,464 | Class A Common Stock |
| Cactus Inc (Class A) | John A. O'Donnell | Director | Other type of transaction at price $ 0.00 per share. | 18 Aug 2023 | 27,508 | 0 | - | - | Units | |
| Cactus Inc (Class A) | John A. O'Donnell | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Aug 2023 | 27,508 | 0 (0%) | 0% | - | Class B Common Stock | |
| Cactus Inc (Class A) | John A. O'Donnell | Director | Other type of transaction at price $ 0.00 per share. | 18 Aug 2023 | 27,508 | 47,821 (0%) | 0% | - | Class A Common Stock | |
| Circor International Inc | John A. O'Donnell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 5,840 | 0 | - | - | Restricted Stock Unit | |
| Circor International Inc | John A. O'Donnell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Aug 2023 | 5,840 | 41,208 (0%) | 0% | - | Common Stock | |
| Ensign Grp Inc | John O. Agwunobi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2023 | 875 | 2,625 (0%) | 0% | 0 | Common Stock | |
| Bluebird bio Inc | John O. Agwunobi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 21,600 | 21,600 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | John O. Agwunobi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 10,790 | 26,464 (0%) | 0% | 0 | Common Stock | |
| Seagen Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 2,044 | 31,047 (0%) | 0% | 0 | Common Stock | |
| Ensign Grp Inc | John O. Agwunobi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2023 | 875 | 1,750 (0%) | 0% | 0 | Common Stock | |
| Circor International Inc | John A. O'Donnell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2023 | 3,780 | 3,780 | - | - | Restricted Stock Unit | |
| Cactus Inc (Class A) | John A. O'Donnell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 2,037 | 3,975 | - | - | Restricted Stock Units | |
| Cactus Inc (Class A) | John A. O'Donnell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 1,938 | 20,313 (0%) | 0% | - | Class A Common Stock | |
| Cactus Inc (Class A) | John A. O'Donnell | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 1,938 | 2,037 | - | - | Restricted Stock Units | |
| Westinghouse Air Brake Tech | John A. Olin | Executive Vice President & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 9,609 | 39,014 (0%) | 0% | 0 | Common Stock - Direct | |
| Westinghouse Air Brake Tech | John A. Olin | Executive Vice President & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 104.90 per share. | 01 Mar 2023 | 1,324 | 29,405 (0%) | 0% | 104.9 | 138,884 | Common Stock - Direct |
| Atreca Inc Ordinary Shares | John A. Orwin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 435,000 | 435,000 | - | - | Employee stock option (right to buy) | |
| Ensign Grp Inc | John O. Agwunobi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2023 | 875 | 875 (0%) | 0% | 0 | Common Stock | |
| Bruker Corp | John A. Ornell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 1,970 | 20,770 (0%) | 0% | 0 | Common Stock | |
| Atreca Inc Ordinary Shares | John A. Orwin | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 1.78 per share. | 02 Sep 2022 | 20,908 | 100,492 (0%) | 0% | 1.8 | 37,116 | Class A Common Stock |
| Circor International Inc | John A. O'Donnell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2022 | 5,840 | 5,840 | - | - | Restricted Stock Unit | |
| Bluebird bio Inc | John O. Agwunobi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Bluebird bio Inc | John O. Agwunobi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 3,109 | 15,674 (0%) | 0% | 0 | Common Stock | |
| Atreca Inc Ordinary Shares | John A. Orwin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 260,000 | 260,000 | - | - | Employee stock option (right to buy) | |
| Atreca Inc Ordinary Shares | John A. Orwin | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Jun 2022 | 260,000 | 0 | - | - | Employee stock option (right to buy) | |
| Atreca Inc Ordinary Shares | John A. Orwin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 241,000 | 241,000 | - | - | Employee stock option (right to buy) | |
| Atreca Inc Ordinary Shares | John A. Orwin | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Jun 2022 | 241,000 | 0 | - | - | Employee stock option (right to buy) | |
| Atreca Inc Ordinary Shares | John A. Orwin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 148,754 | 148,754 | - | - | Employee stock option (right to buy) | |
| Atreca Inc Ordinary Shares | John A. Orwin | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Jun 2022 | 148,754 | 0 | - | - | Employee stock option (right to buy) | |
| Atreca Inc Ordinary Shares | John A. Orwin | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 58,995 | 58,995 | - | - | Employee stock option (right to buy) | |
| Atreca Inc Ordinary Shares | John A. Orwin | Director, President & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 13 Jun 2022 | 58,995 | 0 | - | - | Employee stock option (right to buy) | |
| Seagen Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 3,676 | 3,676 | - | - | Non-Qualified Stock Option (right to buy) | |
| Seagen Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 1,503 | 29,003 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 9,000 | 9,000 | - | - | Stock option (right to buy) | |
| Travere Therapeutics Inc | John A. Orwin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2022 | 3,000 | 17,875 (0%) | 0% | 0 | Common Stock | |
| Herbalife Nutrition Ltd | John O. Agwunobi | Director, Chairman and CEO | Purchase of securities on an exchange or from another person at price $ 23.55 per share. | 10 May 2022 | 4,222 | 134,745 (0%) | 0% | 23.6 | 99,434 | Common Stock |